OnkoSkan™
A revolutionary new test to help detect and monitor cancer
-
Non-invasive blood test to help detect and monitor cancers
- Measures hPG80, a biomarker associated with cancer activity
- CAP/CLIA accredited laboratory
OnkoSkan™ can aid in both the diagnosis and monitoring of cancer.
Through a simple blood test, OnkoSkan™ helps detect the presence of hPG80, a biomarker associated with cancer activity.
The OnkoSkan™ lab test accurately measures hPG80 (circulating progastrin), which is differentially expressed in blood samples from patients with various types of cancer compared to healthy individuals.
hPG80 (Circulating Progastrin), is a new blood based biomarker that detects cancer, and can be used for screening or treatment monitoring purposes.
OnkoSkan™ is based on the principle of a sandwich ELISA to measure the concentration of hPG80 in plasma samples collected in EDTA tubes. The ELISA-based method ensures that the test provides accurate and reproducible results, which are critical for effective patient management
hPG80 is detectable in the blood of patients across 16 different cancer types with concentrations significantly higher than those found in healthy individuals.
OnkoSkan™ can be used for the following cancer types:
Ovarian cancer
Stomach cancer
Liver cancer
Sarcoma
Colorectal cancer
Breast cancer
Melanoma
Esophageal cancer
Lung cancer
Head & neck cancer
Pancreatic cancer
Brain cancer
Neuroendocrine cancer
Kidney cancer
Key Features of OnkoSkan™
Affordable & Easy to Use: Non-invasive blood test
Rapid Turn Around Times: Results delivered in 2-5 business days
Widely Applicable: Applicable to 16 cancer types, across all stages
Dual Use: OnkoSkan can aid in both screening and TRT monitoring
Cancer Screening
hPG80 was detected in the blood of all cancer patients tested, including those for which no markers are available.
hPG80 is therefore expressed at all stages by the tumor, from early stages to metastasis.
Treatment Monitoring
hPG80 was detected across all stages of 16 different types of cancer.[5]
Tested on > 4,000 cancer patients and 1,200 healthy subjects.
Recommended Use of HPG80 Testing
Recommended for adults with elevated risk of cancer
Recommended to be used in addition to routine cancer screening tests
Does not predict cancer signal locations
HPG80 does not diagnose cancer
Who is eligible for OnkoSkan™?
Men – aged 18 or older
Women – aged 18 or older and non-pregnant
Specificity & Sensitivity
Source: https://seer.cancer.gov/
Interpretation of Results:
For Cancer Detection
The median hPG80 value in healthy individuals is 1.50 pmol/L (IQR: 0.32-3.55)
A baseline hPG80 value exceeding 5 pM and/or a consistent increase in hPG80 levels may indicate an elevated risk of developing cancer.
At Diagnosis
High hPG80 levels are associated with poor prognosis.
For Patient Monitoring / Follow-up
A consistent increase in hPG80 levels may indicate a disease progression.
OnkoSkan™ Ordering Process:
Turnaround times: estimated turnaround times of 1 business week.
Specimen Handling & Shipping
Specimens:
Frozen Plasma:
• 2-4mLs of frozen plasma
Whole Blood:
• 8 mLs of whole blood
Handling & Shipping:
Samples must be packaged with dry ice or cold gel packs.
Ensure that labeling is complete.
Ship Overnight to Protean.
For more information, please contact Protean’s support team at support@proteanbiodx.com
You et al. EBioMedicine 2020
The biomarker hPG80 is detectable in the tumor/bloodstream of cancer patients at every stage of tumor progression, from primary tumor to metastasis.
This figure illustrated the high expression of hPG80 by tumor cells from pancreatic and liver cancer (A) and (B) respectively. The tissues peripheral to the tumor masses were devoid of hPG80 immunoreactive cells (C) and (D). Scale bars: 25um.
Contact Us to Order OnkoSkan™
Fill out your name and email address below and someone from Protean’s support team will be in touch shortly.
Questions or Concerns? Contact us at any time.
Phone: 1 (754) 242 9682 | Email: support@proteanbiodx.com
CITATIONS
You, Benoit et al. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. eBioMedicine, Volume 51, 102574
Cappellini, M., Flaceliere, M., Saywell, V., Soule, J., Blanc, E., Belouin, F., Ortiz, E., Canterel-Thouennon, L., Poupeau, S., Tigrett, S., Vire, B., Liaud, P., Blairvacq, M., Joubert, D., & Prieur, A. (2021, September 3). A novel method to detect HPG80 (human circulating progastrin) in the blood. Analytical Methods. https://pubs.rsc.org/en/content/articlelanding/2021/ay/d1ay00986a
Chauhan A, Prieur A, Kolesar J, Arnold S, Payen L, Mahi Y, Vire B, Sands M, Evers BM, Joubert D, et al. hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors. Cancers. 2022; 14(4):863. https://doi.org/10.3390/cancers14040863
Doucet L, Cailleteau A, Vaugier L, et al. Association between post-operative hPG80 (circulating progastrin) detectable level and worse prognosis in glioblastoma. ESMO Open. 2023;8(5):101626. doi:10.1016/j.esmoop.2023.101626
You et al. 2020; Kohli et al. 2021, Dupuy et al. 2022; Chauhan et al. 2022; Prieur et al. 2023; Doucet et al. 2023; Hofman et al. ESMO 203, data on file.
